bendamustine accord 25mg/ml koncentrát pro infuzní roztok
accord healthcare polska sp. z o.o., varšava array - 20883 monohydrÁt bendamustin-hydrochloridu - koncentrát pro infuzní roztok - 25mg/ml - bendamustin
bendamustine accord 2,5mg/ml prášek pro koncentrát pro infuzní roztok
accord healthcare polska sp. z o.o., varšava array - 20883 monohydrÁt bendamustin-hydrochloridu - prášek pro koncentrát pro infuzní roztok - 2,5mg/ml - bendamustin
bendamustine kabi 2,5mg/ml prášek pro koncentrát pro infuzní roztok
fresenius kabi s.r.o., praha array - 3463 bendamustin-hydrochlorid - prášek pro koncentrát pro infuzní roztok - 2,5mg/ml - bendamustin
ledaga
helsinn birex pharmaceuticals ltd. - chlormethine - mykóza fungoides - antineoplastická činidla - ledaga je indikován pro lokální léčbu kožního t-buněčného lymfomu typu mycosis fungoides (mf-type ctcl) u dospělých pacientů.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - mnohočetný myelom - antineoplastická činidla - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
alkeran 2mg potahovaná tableta
aspen pharma trading limited, dublin array - 1571 melfalan - potahovaná tableta - 2mg - melfalan
alkeran 50mg prášek a rozpouštědlo pro injekční/infuzní roztok
aspen pharma trading limited, dublin array - 1571 melfalan - prášek a rozpouštědlo pro injekční/infuzní roztok - 50mg - melfalan
leukeran 2mg potahovaná tableta
aspen pharma trading limited, dublin array - 1741 chlorambucil - potahovaná tableta - 2mg - chlorambucil
melphalan zentiva 50mg prášek a rozpouštědlo pro injekční/infuzní roztok
zentiva, k.s., praha array - 21067 melfalan-hydrochlorid - prášek a rozpouštědlo pro injekční/infuzní roztok - 50mg - melfalan
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastická činidla - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.